Abbott Determined To Improve Image Of HIV Tests After Regulatory Setbacks
This article was originally published in The Gray Sheet
Executive Summary
Applications submitted by African countries for Abbott's Determine rapid HIV diagnostic test will be evaluated by health care consulting firm Axios International at the end of April, Abbott said March 27.
You may also be interested in...
OraSure's OraQuick
CDC selects firm's rapid HIV-1/2 test under treatment investigational device exemption granted by FDA, OraSure announces March 15. CDC is focusing use of test in public hospitals in five U.S. cities for delivery room testing, as well as emergency departments and outpatient clinics. No rapid HIV test currently is marketed in the U.S.; the agency authorized continued use of the investigational test by CDC because it addresses a serious and life-threatening condition for which no alternatives exist. Abbott's SUDS HIV-1 rapid test was temporarily withdrawn from the market due to quality control issues (1"The Gray Sheet" Oct. 23, 2000, p. 24). Trinity Biotech's Feb. 5 premarket approval application for Uni-Gold rapid HIV test is pending at FDA
Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits
A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.